NEW YORK (GenomeWeb News) – Epigenomics today announced that a US Food and Drug Administration panel voted in favor of the company’s Epi proColon colorectal cancer screening test but with concerns.

In a meeting held on Wednesday, the Molecular and Clinical Genetics Panel of FDA's Medical Devices Advisory Committee voted that the benefits of the test outweigh the risk for use in patients "who meet the criteria," Epigenomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.